India
Founded in 2004, the India-based company has over 75 years of experience serving the pharmaceutical industry. Bioplus is committed to advancing in Biotechnology while maintaining its global partnerships in Contract Manufacturing and EU/ANZ pharma generic pharmaceuticals. The company's focus on utilizing its advanced skill set in Biotechnology has led to its emergence as a late-stage clinical phase company with 2 programs for large global unmet needs, both of which are Clinical phase 3 ready.
Bioplus aims to partner with leading companies regionally or globally to optimize product market access, while also fostering a rich pipeline of pre-clinical programs. They anticipate significant growth in the next 5 years as their global block buster Novel therapeutics enter the market. Wealth management firm AIF Capital participated in their Private Equity Round investment at 01 June 2008. The company remains devoted to substantial investments in R&D and Clinical Development and is keen on contributing to the health and well-being of global citizens.
